Gene

Olaparib

Abiraterone

Prostate cancer

Abiraterone acetate

Cohort

Surgery

Androgen deprivation therapy

Biochemistry

Poly ADP ribose polymerase

Enzalutamide

Overall survival

Androgen receptor

Progression-free survival

Polymerase

Internal medicine

Clinical endpoint

Chemotherapy

Confidence interval

Hazard ratio

Oncology

Medicine

Chemistry

Disease

Cancer

Randomized controlled trial

New England Journal of Medicine

We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician’s choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer